Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-02

AUTHORS

M. Dehesa, J. Larisch, M. Dibildox, M. Di Silvio, L. H. Lopez, E. Ramirez-Barba, J. Torres

ABSTRACT

Objective: To compare the efficacy and tolerability of three 7-day pantoprazole-based regimens to eradicate Helicobacter pylori in Mexican patients with peptic ulcer (PU) or non-ulcer dyspepsia (NUD).Background: Short-term therapeutic regimens based on a proton pump inhibitor (PPI) and two antibiotics have been recommended for the eradication of H. pylori. Resistance of H. pylori to metronidazole may adversely affect the efficacy of such regimens.Patients and methods: This was a single-centre, randomised, open-label, parallel-group study in which three groups of H. pylori-positive patients with PU or NUD were compared (n = 159; intention-to-treat population). Patients were randomised to receive a 7-day pantoprazole-based triple therapy for eradication of H. pylori. Patients received pantoprazole (P) 40mg twice daily in combination with either i) amoxicillin (A) 1000mg twice daily and clarithromycin (C) 500mg three times daily (PAC regimen, n = 51 patients), or ii) clarithromycin 500mg three times daily and metronidazole (M) 500mg three times daily (PCM regimen, n = 55 patients), or iii) amoxicillin 1000mg twice daily and metronidazole 500mg three times daily (PAM regimen, n = 53 patients). After completing eradication therapy, all PU patients were further treated with once-daily pantoprazole 40mg, either for another 3 weeks (patients with duodenal ulcer) or for another 7 weeks (patients with gastric ulcer), to ensure complete ulcer healing. At baseline examination, all patients underwent the 14C-urea breath test and endoscopy; biopsy specimens were taken for histology, CLO-test, H. pylori culture and antibiotic susceptibility testing (agar dilution E-test). Eradication of H. pylori was assessed after all treatment with pantoprazole had been discontinued for at least 4 weeks, using the 14C-urea breath test.Results: In the per-protocol population (n = 153), eradication was achieved in 81.3% (39/48) of patients receiving PAC, 66.0% (35/53) of PCM recipients, and 48.1 % (25/52) of those receiving PAM (p = 0.13 for PAC vs PCM and 0.001 for PAC vs PAM). In the intention-to-treat population, respective eradication rates were 76.5 (39/51), 63.6 (35/55) and 47.2% (25/53) [p = 0.22 for PAC vs PCM and 0.004 for PAC vs PAM]. Patient compliance was very good in all treatment groups. The main adverse event affecting 40% of all patients was a metallic taste, assessed as likely related to the antibiotics. Susceptibility to the three study antibiotics was determined for H. pylori isolates using the pretreatment biopsies from 103 patients. Resistance to metronidazole was present in 68.2% of patients and to clarithromycin in 24.3%. In 16.8% of patients, H. pylori isolates were resistant to both metronidazole and clarithromycin. In patient populations with H. pylori strains resistant to one or both of the antibiotics used in the respective treatment regimen, eradication rates were consistently lower than in those with susceptible H. pylori strains. However, these differences were not statistically significant, probably due to the small sample size.Conclusions: The 7-day H. pylori eradication regimen with PAC was superior to PCM and PAM. This is probably due to the high resistance rate to metronidazole in the Mexican population. Thus, H. pylori eradication regimens that involve metronidazole cannot be recommended for Mexican patients. Results from this study highlight the regional differences in efficacy of some well established H. pylori eradication regimens, and suggest that culture and susceptibility testing to define H. pylori resistance patterns in specific geographical areas may be indicated before recommending any particular eradication schedule. More... »

PAGES

75-85

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00044011-200222020-00002

DOI

http://dx.doi.org/10.2165/00044011-200222020-00002

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006298290

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23315395


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hospital Especialidades, Centro M\u00e9dico Nacional Siglo XXI IMSS, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.418385.3", 
          "name": [
            "Hospital Especialidades, Centro M\u00e9dico Nacional Siglo XXI IMSS, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dehesa", 
        "givenName": "M.", 
        "id": "sg:person.0637740256.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637740256.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Especialidades, Centro M\u00e9dico Nacional Siglo XXI IMSS, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.418385.3", 
          "name": [
            "Hospital Especialidades, Centro M\u00e9dico Nacional Siglo XXI IMSS, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larisch", 
        "givenName": "J.", 
        "id": "sg:person.01225607072.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225607072.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Investigaci\u00f3n Cl\u00ednica, BYK Gulden, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Investigaci\u00f3n Cl\u00ednica, BYK Gulden, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dibildox", 
        "givenName": "M.", 
        "id": "sg:person.01047715072.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047715072.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Investigaci\u00f3n Cl\u00ednica, BYK Gulden, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Investigaci\u00f3n Cl\u00ednica, BYK Gulden, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Silvio", 
        "givenName": "M.", 
        "id": "sg:person.0617240072.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617240072.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Investigaci\u00f3n Cl\u00ednica, BYK Gulden, Mexico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Investigaci\u00f3n Cl\u00ednica, BYK Gulden, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lopez", 
        "givenName": "L. H.", 
        "id": "sg:person.01235761070.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235761070.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unidad de Investigaci\u00f3n, Facultad de Medicina, Universidad de Guanajuato, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.412891.7", 
          "name": [
            "Unidad de Investigaci\u00f3n, Facultad de Medicina, Universidad de Guanajuato, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramirez-Barba", 
        "givenName": "E.", 
        "id": "sg:person.01072316656.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072316656.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro M\u00e9dico Nacional Siglo XXI, IMSS, Hospital de Pediatr\u00eda, Unidad de Investigaci\u00f3n en Enfermedades Infecciosas, Mexico", 
          "id": "http://www.grid.ac/institutes/grid.418385.3", 
          "name": [
            "Centro M\u00e9dico Nacional Siglo XXI, IMSS, Hospital de Pediatr\u00eda, Unidad de Investigaci\u00f3n en Enfermedades Infecciosas, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Torres", 
        "givenName": "J.", 
        "id": "sg:person.015143011577.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015143011577.78"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1111/j.1572-0241.1998.002_c.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008860064", 
          "https://doi.org/10.1111/j.1572-0241.1998.002_c.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2001.03519.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027798404", 
          "https://doi.org/10.1111/j.1572-0241.2001.03519.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.1998.00212.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002983887", 
          "https://doi.org/10.1111/j.1572-0241.1998.00212.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.1999.01202.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043526083", 
          "https://doi.org/10.1111/j.1572-0241.1999.01202.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.1998.00386.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017811267", 
          "https://doi.org/10.1111/j.1572-0241.1998.00386.x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-02", 
    "datePublishedReg": "2002-02-01", 
    "description": "Objective: To compare the efficacy and tolerability of three 7-day pantoprazole-based regimens to eradicate Helicobacter pylori in Mexican patients with peptic ulcer (PU) or non-ulcer dyspepsia (NUD).Background: Short-term therapeutic regimens based on a proton pump inhibitor (PPI) and two antibiotics have been recommended for the eradication of H. pylori. Resistance of H. pylori to metronidazole may adversely affect the efficacy of such regimens.Patients and methods: This was a single-centre, randomised, open-label, parallel-group study in which three groups of H. pylori-positive patients with PU or NUD were compared (n = 159; intention-to-treat population). Patients were randomised to receive a 7-day pantoprazole-based triple therapy for eradication of H. pylori. Patients received pantoprazole (P) 40mg twice daily in combination with either i) amoxicillin (A) 1000mg twice daily and clarithromycin (C) 500mg three times daily (PAC regimen, n = 51 patients), or ii) clarithromycin 500mg three times daily and metronidazole (M) 500mg three times daily (PCM regimen, n = 55 patients), or iii) amoxicillin 1000mg twice daily and metronidazole 500mg three times daily (PAM regimen, n = 53 patients). After completing eradication therapy, all PU patients were further treated with once-daily pantoprazole 40mg, either for another 3 weeks (patients with duodenal ulcer) or for another 7 weeks (patients with gastric ulcer), to ensure complete ulcer healing. At baseline examination, all patients underwent the 14C-urea breath test and endoscopy; biopsy specimens were taken for histology, CLO-test, H. pylori culture and antibiotic susceptibility testing (agar dilution E-test). Eradication of H. pylori was assessed after all treatment with pantoprazole had been discontinued for at least 4 weeks, using the 14C-urea breath test.Results: In the per-protocol population (n = 153), eradication was achieved in 81.3% (39/48) of patients receiving PAC, 66.0% (35/53) of PCM recipients, and 48.1 % (25/52) of those receiving PAM (p = 0.13 for PAC vs PCM and 0.001 for PAC vs PAM). In the intention-to-treat population, respective eradication rates were 76.5 (39/51), 63.6 (35/55) and 47.2% (25/53) [p = 0.22 for PAC vs PCM and 0.004 for PAC vs PAM]. Patient compliance was very good in all treatment groups. The main adverse event affecting 40% of all patients was a metallic taste, assessed as likely related to the antibiotics. Susceptibility to the three study antibiotics was determined for H. pylori isolates using the pretreatment biopsies from 103 patients. Resistance to metronidazole was present in 68.2% of patients and to clarithromycin in 24.3%. In 16.8% of patients, H. pylori isolates were resistant to both metronidazole and clarithromycin. In patient populations with H. pylori strains resistant to one or both of the antibiotics used in the respective treatment regimen, eradication rates were consistently lower than in those with susceptible H. pylori strains. However, these differences were not statistically significant, probably due to the small sample size.Conclusions: The 7-day H. pylori eradication regimen with PAC was superior to PCM and PAM. This is probably due to the high resistance rate to metronidazole in the Mexican population. Thus, H. pylori eradication regimens that involve metronidazole cannot be recommended for Mexican patients. Results from this study highlight the regional differences in efficacy of some well established H. pylori eradication regimens, and suggest that culture and susceptibility testing to define H. pylori resistance patterns in specific geographical areas may be indicated before recommending any particular eradication schedule.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00044011-200222020-00002", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "non-ulcer dyspepsia", 
      "pylori eradication regimens", 
      "proton pump inhibitors", 
      "peptic ulcer", 
      "amoxicillin 1000", 
      "eradication rate", 
      "eradication regimens", 
      "Mexican patients", 
      "breath test", 
      "pylori isolates", 
      "pantoprazole-based triple therapy", 
      "susceptibility testing", 
      "Helicobacter pylori eradication regimens", 
      "complete ulcer healing", 
      "respective eradication rates", 
      "respective treatment regimen", 
      "pylori resistance patterns", 
      "high metronidazole resistance", 
      "main adverse events", 
      "parallel-group study", 
      "pylori eradication regimen", 
      "pylori-positive patients", 
      "high resistance rates", 
      "Mexican population", 
      "antibiotic susceptibility testing", 
      "daily pantoprazole", 
      "triple therapy", 
      "protocol population", 
      "treat population", 
      "eradication therapy", 
      "eradication regimen", 
      "pylori eradication", 
      "ulcer healing", 
      "baseline examination", 
      "adverse events", 
      "pretreatment biopsies", 
      "treatment regimen", 
      "such regimens", 
      "PU patients", 
      "therapeutic regimens", 
      "pump inhibitors", 
      "patient population", 
      "biopsy specimens", 
      "study antibiotics", 
      "metronidazole resistance", 
      "patient compliance", 
      "resistance rates", 
      "treatment groups", 
      "resistance patterns", 
      "regimens", 
      "patients", 
      "pylori culture", 
      "Helicobacter pylori", 
      "pylori strains", 
      "pylori", 
      "clarithromycin", 
      "metronidazole", 
      "metallic taste", 
      "pantoprazole", 
      "small sample size", 
      "eradication", 
      "antibiotics", 
      "weeks", 
      "regimen", 
      "efficacy", 
      "therapy", 
      "population", 
      "sample size", 
      "tolerability", 
      "dyspepsia", 
      "regional differences", 
      "ulcers", 
      "biopsy", 
      "group", 
      "isolates", 
      "endoscopy", 
      "histology", 
      "recipients", 
      "study highlight", 
      "healing", 
      "rate", 
      "treatment", 
      "differences", 
      "specific geographical area", 
      "testing", 
      "inhibitors", 
      "resistance", 
      "geographical areas", 
      "examination", 
      "test", 
      "compliance", 
      "culture", 
      "susceptibility", 
      "time", 
      "schedule", 
      "PAM", 
      "study", 
      "specimens", 
      "events", 
      "PAC", 
      "strains", 
      "combination", 
      "patterns", 
      "taste", 
      "three", 
      "intention", 
      "comparison", 
      "area", 
      "results", 
      "highlights", 
      "size", 
      "method", 
      "PCM", 
      "pantoprazole-based regimens", 
      "Short-term therapeutic regimens", 
      "PCM recipients", 
      "H. pylori eradication regimen", 
      "particular eradication schedule", 
      "eradication schedule", 
      "Comparison of Three"
    ], 
    "name": "Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance", 
    "pagination": "75-85", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006298290"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00044011-200222020-00002"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23315395"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00044011-200222020-00002", 
      "https://app.dimensions.ai/details/publication/pub.1006298290"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_361.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00044011-200222020-00002"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00044011-200222020-00002'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00044011-200222020-00002'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00044011-200222020-00002'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00044011-200222020-00002'


 

This table displays all metadata directly associated to this object as RDF triples.

252 TRIPLES      22 PREDICATES      152 URIs      139 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00044011-200222020-00002 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ndffefec5cbc441318d677b114f32b2a6
4 schema:citation sg:pub.10.1111/j.1572-0241.1998.00212.x
5 sg:pub.10.1111/j.1572-0241.1998.002_c.x
6 sg:pub.10.1111/j.1572-0241.1998.00386.x
7 sg:pub.10.1111/j.1572-0241.1999.01202.x
8 sg:pub.10.1111/j.1572-0241.2001.03519.x
9 schema:datePublished 2002-02
10 schema:datePublishedReg 2002-02-01
11 schema:description Objective: To compare the efficacy and tolerability of three 7-day pantoprazole-based regimens to eradicate Helicobacter pylori in Mexican patients with peptic ulcer (PU) or non-ulcer dyspepsia (NUD).Background: Short-term therapeutic regimens based on a proton pump inhibitor (PPI) and two antibiotics have been recommended for the eradication of H. pylori. Resistance of H. pylori to metronidazole may adversely affect the efficacy of such regimens.Patients and methods: This was a single-centre, randomised, open-label, parallel-group study in which three groups of H. pylori-positive patients with PU or NUD were compared (n = 159; intention-to-treat population). Patients were randomised to receive a 7-day pantoprazole-based triple therapy for eradication of H. pylori. Patients received pantoprazole (P) 40mg twice daily in combination with either i) amoxicillin (A) 1000mg twice daily and clarithromycin (C) 500mg three times daily (PAC regimen, n = 51 patients), or ii) clarithromycin 500mg three times daily and metronidazole (M) 500mg three times daily (PCM regimen, n = 55 patients), or iii) amoxicillin 1000mg twice daily and metronidazole 500mg three times daily (PAM regimen, n = 53 patients). After completing eradication therapy, all PU patients were further treated with once-daily pantoprazole 40mg, either for another 3 weeks (patients with duodenal ulcer) or for another 7 weeks (patients with gastric ulcer), to ensure complete ulcer healing. At baseline examination, all patients underwent the 14C-urea breath test and endoscopy; biopsy specimens were taken for histology, CLO-test, H. pylori culture and antibiotic susceptibility testing (agar dilution E-test). Eradication of H. pylori was assessed after all treatment with pantoprazole had been discontinued for at least 4 weeks, using the 14C-urea breath test.Results: In the per-protocol population (n = 153), eradication was achieved in 81.3% (39/48) of patients receiving PAC, 66.0% (35/53) of PCM recipients, and 48.1 % (25/52) of those receiving PAM (p = 0.13 for PAC vs PCM and 0.001 for PAC vs PAM). In the intention-to-treat population, respective eradication rates were 76.5 (39/51), 63.6 (35/55) and 47.2% (25/53) [p = 0.22 for PAC vs PCM and 0.004 for PAC vs PAM]. Patient compliance was very good in all treatment groups. The main adverse event affecting 40% of all patients was a metallic taste, assessed as likely related to the antibiotics. Susceptibility to the three study antibiotics was determined for H. pylori isolates using the pretreatment biopsies from 103 patients. Resistance to metronidazole was present in 68.2% of patients and to clarithromycin in 24.3%. In 16.8% of patients, H. pylori isolates were resistant to both metronidazole and clarithromycin. In patient populations with H. pylori strains resistant to one or both of the antibiotics used in the respective treatment regimen, eradication rates were consistently lower than in those with susceptible H. pylori strains. However, these differences were not statistically significant, probably due to the small sample size.Conclusions: The 7-day H. pylori eradication regimen with PAC was superior to PCM and PAM. This is probably due to the high resistance rate to metronidazole in the Mexican population. Thus, H. pylori eradication regimens that involve metronidazole cannot be recommended for Mexican patients. Results from this study highlight the regional differences in efficacy of some well established H. pylori eradication regimens, and suggest that culture and susceptibility testing to define H. pylori resistance patterns in specific geographical areas may be indicated before recommending any particular eradication schedule.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf N863cba04fea1449db4fd390d2aaa0c78
16 Nf42744748009405b90d393fec23e0ca7
17 sg:journal.1100199
18 schema:keywords Comparison of Three
19 H. pylori eradication regimen
20 Helicobacter pylori
21 Helicobacter pylori eradication regimens
22 Mexican patients
23 Mexican population
24 PAC
25 PAM
26 PCM
27 PCM recipients
28 PU patients
29 Short-term therapeutic regimens
30 adverse events
31 amoxicillin 1000
32 antibiotic susceptibility testing
33 antibiotics
34 area
35 baseline examination
36 biopsy
37 biopsy specimens
38 breath test
39 clarithromycin
40 combination
41 comparison
42 complete ulcer healing
43 compliance
44 culture
45 daily pantoprazole
46 differences
47 dyspepsia
48 efficacy
49 endoscopy
50 eradication
51 eradication rate
52 eradication regimen
53 eradication regimens
54 eradication schedule
55 eradication therapy
56 events
57 examination
58 geographical areas
59 group
60 healing
61 high metronidazole resistance
62 high resistance rates
63 highlights
64 histology
65 inhibitors
66 intention
67 isolates
68 main adverse events
69 metallic taste
70 method
71 metronidazole
72 metronidazole resistance
73 non-ulcer dyspepsia
74 pantoprazole
75 pantoprazole-based regimens
76 pantoprazole-based triple therapy
77 parallel-group study
78 particular eradication schedule
79 patient compliance
80 patient population
81 patients
82 patterns
83 peptic ulcer
84 population
85 pretreatment biopsies
86 protocol population
87 proton pump inhibitors
88 pump inhibitors
89 pylori
90 pylori culture
91 pylori eradication
92 pylori eradication regimen
93 pylori eradication regimens
94 pylori isolates
95 pylori resistance patterns
96 pylori strains
97 pylori-positive patients
98 rate
99 recipients
100 regimen
101 regimens
102 regional differences
103 resistance
104 resistance patterns
105 resistance rates
106 respective eradication rates
107 respective treatment regimen
108 results
109 sample size
110 schedule
111 size
112 small sample size
113 specific geographical area
114 specimens
115 strains
116 study
117 study antibiotics
118 study highlight
119 such regimens
120 susceptibility
121 susceptibility testing
122 taste
123 test
124 testing
125 therapeutic regimens
126 therapy
127 three
128 time
129 tolerability
130 treat population
131 treatment
132 treatment groups
133 treatment regimen
134 triple therapy
135 ulcer healing
136 ulcers
137 weeks
138 schema:name Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance
139 schema:pagination 75-85
140 schema:productId N01708d9c7eb548389308140831e41550
141 N3fcce90f8fbb462aad91fdcedb6bbaf1
142 N58d8e43b69eb44aeac83786c1b0f2a59
143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006298290
144 https://doi.org/10.2165/00044011-200222020-00002
145 schema:sdDatePublished 2022-01-01T18:12
146 schema:sdLicense https://scigraph.springernature.com/explorer/license/
147 schema:sdPublisher N834d68d0de054222852ba471f6a59601
148 schema:url https://doi.org/10.2165/00044011-200222020-00002
149 sgo:license sg:explorer/license/
150 sgo:sdDataset articles
151 rdf:type schema:ScholarlyArticle
152 N01708d9c7eb548389308140831e41550 schema:name dimensions_id
153 schema:value pub.1006298290
154 rdf:type schema:PropertyValue
155 N01ee820244e043a982322b0dd6d2b4f8 rdf:first sg:person.015143011577.78
156 rdf:rest rdf:nil
157 N0a6dfd3edb994a78a3bfc67b3a16e1a3 rdf:first sg:person.0617240072.38
158 rdf:rest Ncc3c97cc2d8248b4a6e6d650c9d055b3
159 N0f927d5a08cf4cc7a956dc095ab8c473 rdf:first sg:person.01047715072.68
160 rdf:rest N0a6dfd3edb994a78a3bfc67b3a16e1a3
161 N3fcce90f8fbb462aad91fdcedb6bbaf1 schema:name doi
162 schema:value 10.2165/00044011-200222020-00002
163 rdf:type schema:PropertyValue
164 N43cd925f151042dabadd938bc282d487 rdf:first sg:person.01072316656.41
165 rdf:rest N01ee820244e043a982322b0dd6d2b4f8
166 N58d8e43b69eb44aeac83786c1b0f2a59 schema:name pubmed_id
167 schema:value 23315395
168 rdf:type schema:PropertyValue
169 N834d68d0de054222852ba471f6a59601 schema:name Springer Nature - SN SciGraph project
170 rdf:type schema:Organization
171 N863cba04fea1449db4fd390d2aaa0c78 schema:volumeNumber 22
172 rdf:type schema:PublicationVolume
173 Nabc72f981e8c4b0d915fb2b54424de6c rdf:first sg:person.01225607072.58
174 rdf:rest N0f927d5a08cf4cc7a956dc095ab8c473
175 Ncc3c97cc2d8248b4a6e6d650c9d055b3 rdf:first sg:person.01235761070.11
176 rdf:rest N43cd925f151042dabadd938bc282d487
177 Ndffefec5cbc441318d677b114f32b2a6 rdf:first sg:person.0637740256.83
178 rdf:rest Nabc72f981e8c4b0d915fb2b54424de6c
179 Nf42744748009405b90d393fec23e0ca7 schema:issueNumber 2
180 rdf:type schema:PublicationIssue
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
185 schema:name Clinical Sciences
186 rdf:type schema:DefinedTerm
187 sg:journal.1100199 schema:issn 1173-2563
188 1179-1918
189 schema:name Clinical Drug Investigation
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01047715072.68 schema:affiliation grid-institutes:None
193 schema:familyName Dibildox
194 schema:givenName M.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047715072.68
196 rdf:type schema:Person
197 sg:person.01072316656.41 schema:affiliation grid-institutes:grid.412891.7
198 schema:familyName Ramirez-Barba
199 schema:givenName E.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072316656.41
201 rdf:type schema:Person
202 sg:person.01225607072.58 schema:affiliation grid-institutes:grid.418385.3
203 schema:familyName Larisch
204 schema:givenName J.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225607072.58
206 rdf:type schema:Person
207 sg:person.01235761070.11 schema:affiliation grid-institutes:None
208 schema:familyName Lopez
209 schema:givenName L. H.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235761070.11
211 rdf:type schema:Person
212 sg:person.015143011577.78 schema:affiliation grid-institutes:grid.418385.3
213 schema:familyName Torres
214 schema:givenName J.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015143011577.78
216 rdf:type schema:Person
217 sg:person.0617240072.38 schema:affiliation grid-institutes:None
218 schema:familyName Di Silvio
219 schema:givenName M.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617240072.38
221 rdf:type schema:Person
222 sg:person.0637740256.83 schema:affiliation grid-institutes:grid.418385.3
223 schema:familyName Dehesa
224 schema:givenName M.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637740256.83
226 rdf:type schema:Person
227 sg:pub.10.1111/j.1572-0241.1998.00212.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002983887
228 https://doi.org/10.1111/j.1572-0241.1998.00212.x
229 rdf:type schema:CreativeWork
230 sg:pub.10.1111/j.1572-0241.1998.002_c.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008860064
231 https://doi.org/10.1111/j.1572-0241.1998.002_c.x
232 rdf:type schema:CreativeWork
233 sg:pub.10.1111/j.1572-0241.1998.00386.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017811267
234 https://doi.org/10.1111/j.1572-0241.1998.00386.x
235 rdf:type schema:CreativeWork
236 sg:pub.10.1111/j.1572-0241.1999.01202.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043526083
237 https://doi.org/10.1111/j.1572-0241.1999.01202.x
238 rdf:type schema:CreativeWork
239 sg:pub.10.1111/j.1572-0241.2001.03519.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027798404
240 https://doi.org/10.1111/j.1572-0241.2001.03519.x
241 rdf:type schema:CreativeWork
242 grid-institutes:None schema:alternateName Investigación Clínica, BYK Gulden, Mexico
243 schema:name Investigación Clínica, BYK Gulden, Mexico
244 rdf:type schema:Organization
245 grid-institutes:grid.412891.7 schema:alternateName Unidad de Investigación, Facultad de Medicina, Universidad de Guanajuato, Mexico
246 schema:name Unidad de Investigación, Facultad de Medicina, Universidad de Guanajuato, Mexico
247 rdf:type schema:Organization
248 grid-institutes:grid.418385.3 schema:alternateName Centro Médico Nacional Siglo XXI, IMSS, Hospital de Pediatría, Unidad de Investigación en Enfermedades Infecciosas, Mexico
249 Hospital Especialidades, Centro Médico Nacional Siglo XXI IMSS, Mexico
250 schema:name Centro Médico Nacional Siglo XXI, IMSS, Hospital de Pediatría, Unidad de Investigación en Enfermedades Infecciosas, Mexico
251 Hospital Especialidades, Centro Médico Nacional Siglo XXI IMSS, Mexico
252 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...